Kimberly D. Hill

629 total citations
12 papers, 502 citations indexed

About

Kimberly D. Hill is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Kimberly D. Hill has authored 12 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Kimberly D. Hill's work include Cancer Treatment and Pharmacology (2 papers), Cancer therapeutics and mechanisms (2 papers) and Click Chemistry and Applications (1 paper). Kimberly D. Hill is often cited by papers focused on Cancer Treatment and Pharmacology (2 papers), Cancer therapeutics and mechanisms (2 papers) and Click Chemistry and Applications (1 paper). Kimberly D. Hill collaborates with scholars based in United States and South Africa. Kimberly D. Hill's co-authors include Sherman F. Stinson, Richard M. Lush, A Tompkins, Edward A. Sausville, Susan G. Arbuck, Seth M. Steinberg, Donna Headlee, William D. Figg, Adrian M. Senderowicz and Eva Majerová and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kimberly D. Hill

11 papers receiving 483 citations

Peers

Countries citing papers authored by Kimberly D. Hill

Since Specialization

Citations

This map shows the geographic impact of Kimberly D. Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly D. Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly D. Hill more than expected).

Fields of papers citing papers by Kimberly D. Hill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly D. Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly D. Hill. The network helps show where Kimberly D. Hill may publish in the future.

Co-authorship network of co-authors of Kimberly D. Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly D. Hill. A scholar is included among the top collaborators of Kimberly D. Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly D. Hill. Kimberly D. Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models 2024 ·Cell Reports ·Sebastian Schmid, (unknown), Alex Shimura Yamashita, (unknown), (unknown), (unknown), (unknown), (unknown), David Quist, (unknown), (unknown), Kimberly D. Hill, Larry W. Anderson, Patrick J. Cimino, Debra K Kumasaka, Ralph E. Parchment, Eric C. Holland, Frank Szulzewsky	1
2	Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation 2019 ·Clinical Cancer Research ·Timothy J. Kinsella, Howard Safran, Susan R. Wiersma, Thomas A. DiPetrillo, Andrew Schumacher, (unknown), (unknown), Lawrence W. Anderson, Kimberly D. Hill, Charles A. Kunos, Jerry M. Collins	4
3	Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases 2017 ·Biochemical Pharmacology ·Jiamo Lu, Prabhakar Risbood, (unknown), (unknown), Larry Anderson, Kimberly D. Hill, Anne Monks, Yongzhong Wu, Smitha Antony, Ágnes Juhász, Han Liu, Guojian Jiang, Erik Harris, Krishnendu Roy, Jennifer L. Meitzler, Mariam M. Konaté, James H. Doroshow	25
4	Abstract 4351: Effects of epigenetic agents on methylation of DNA in vitro and in vivo, as measured with stable isotopically labeled methionine 2017 ·Cancer Research ·Lawrence W. Anderson, Eva Majerová, Kimberly D. Hill, John Carter, (unknown), Howard Stotler, Melinda G. Hollingshead, Jerry M. Collins	1
5	Neutrophil function in healthy aged horses and horses with pituitary dysfunction 2015 ·Veterinary Immunology and Immunopathology ·Dianne McFarlane, Kimberly D. Hill, (unknown)	23
6	First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies 2013 ·Clinical Cancer Research ·Shivaani Kummar, Larry Anderson, Kimberly D. Hill, Eva Majerová, Deborah Allen, Yvonne Horneffer, S. Percy Ivy, Larry Rubinstein, Pamela Jo Harris, James H. Doroshow, Jerry M. Collins	18
7	High-Throughput Screening of a Diversity Collection Using Biodefense Category A and B Priority Pathogens 2012 ·SLAS DISCOVERY ·Esther W. Barrow, (unknown), (unknown), (unknown), Kimberly D. Hill, Philip C. Bourne, Michelle Wright Valderas, Christina R. Bourne, (unknown), Kenneth D. Clinkenbeard, William W. Barrow	4
8	Liquid Chromatographic Determination of NSC 737664 (ABT-888: An Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial 2008 ·Journal of Liquid Chromatography & Related Technologies ·Lawrence R. Phillips, Kimberly D. Hill, Eva Majerová	7
9	Design, Synthesis, and Evaluation of In Vivo Potency and Selectivity of Epoxysuccinyl-Based Inhibitors of Papain-Family Cysteine Proteases 2007 ·Chemistry & Biology ·Amir Masoud Sadaghiani, Steven H. L. Verhelst, Vasilena Gocheva, Kimberly D. Hill, Eva Majerová, Sherman F. Stinson, Johanna A. Joyce, Matthew Bogyo	56
10	Determination of Retinyl Palmitate (Vitamin A) in Fortified Fluid Milk by Liquid Chromatography: Collaborative Study 2003 ·Journal of AOAC International ·(unknown), (unknown), (unknown), (unknown), (unknown), Estelle Bonnin, (unknown), Charles N. Ellis, H Faulkner, (unknown), David Goins, Kimberly D. Hill, (unknown), (unknown), J.L. McGuire, (unknown), David N. O’Neal, (unknown), (unknown), C. Wagner	7
11	Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection 1998 ·Cancer Chemotherapy and Pharmacology ·Sherman F. Stinson, Kimberly D. Hill, (unknown), Lawrence R. Phillips, (unknown)	18
12	Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. 1998 ·Journal of Clinical Oncology ·Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson, Richard M. Lush, (unknown), (unknown), Kimberly D. Hill, Seth M. Steinberg, William D. Figg, A Tompkins, Susan G. Arbuck, Edward A. Sausville	338

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact